Litigation Details for Allergan, Inc. v. Watson Pharmaceuticals, Inc. (Fed. Cir. 2013)

Allergan, Inc. v. Watson Pharmaceuticals, Inc. (Fed. Cir. 2013)

Docket		Date Filed	2013-03-14
Court	Court of Appeals for the Federal Circuit	Date Terminated	2013-05-06
Cause		Assigned To
Jury Demand		Referred To
Patents	6,403,649; 7,351,404; 7,388,029; 8,038,988; 8,101,161
Link to Docket	External link to docket

Details for Allergan, Inc. v. Watson Pharmaceuticals, Inc. (Fed. Cir. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-03-14				External link to document

Allergan v. Watson Pharmaceuticals, Inc. 13-1249: Litigation Summary and Patent Analysis

Last updated: August 30, 2026

Allergan, Inc. v. Watson Pharmaceuticals, Inc., No. 13-1249, involved Watson’s abbreviated new drug application for a generic version of Allergan’s Lumigan 0.01% ophthalmic solution, an ophthalmic bimatoprost product used to reduce elevated intraocular pressure in patients with glaucoma or ocular hypertension. The dispute centered on whether Watson’s proposed product infringed Allergan’s formulation patent and whether the asserted claims were invalid for obviousness.

The Federal Circuit affirmed the district court’s judgment for Allergan. The decision preserved Allergan’s ability to block immediate generic entry based on the asserted patent and reinforced the importance of formulation-specific evidence in Hatch-Waxman litigation involving ophthalmic products. [1]

What drug and patents were involved in Allergan v. Watson?

The case concerned Lumigan 0.01%, whose active ingredient is bimatoprost.

Item	Case-relevant information
Brand product	Lumigan 0.01% ophthalmic solution
Active ingredient	Bimatoprost
Therapeutic use	Reduction of elevated intraocular pressure
Disease areas	Glaucoma and ocular hypertension
Brand company	Allergan, Inc.
Generic applicant	Watson Pharmaceuticals, Inc.
Regulatory pathway	ANDA under the Hatch-Waxman Act
Federal Circuit docket	No. 13-1249
Principal patent issue	Validity and infringement of Allergan’s low-concentration bimatoprost formulation patent

The asserted patent was U.S. Patent No. 7,851,504, which covered an ophthalmic composition containing 0.01% bimatoprost. The patent distinguished the commercial formulation from earlier bimatoprost products, including Lumigan 0.03%, through a lower active-ingredient concentration and associated reduction in ocular hyperemia, commonly known as eye redness. [1]

What formulation was protected?

The patent protected an ophthalmic formulation containing bimatoprost at the 0.01% concentration. The commercial significance was the formulation’s ability to maintain intraocular-pressure-lowering efficacy while reducing the incidence and severity of hyperemia associated with higher-concentration bimatoprost products.

The asserted claims were formulation claims rather than claims limited solely to a manufacturing process. This distinction mattered because Watson’s ANDA product was alleged to have the same or materially equivalent concentration and composition as the patented Lumigan formulation.

What was the legal dispute in the Watson patent litigation?

Allergan sued after Watson filed an ANDA seeking FDA approval to market a generic bimatoprost ophthalmic solution. Watson’s ANDA filing triggered a Paragraph IV certification asserting that the Allergan patent was invalid, unenforceable, or would not be infringed by Watson’s proposed product.

The principal issues were:

1. Whether Watson’s proposed product infringed the asserted patent.
2. Whether the claimed 0.01% bimatoprost formulation was obvious in view of prior-art bimatoprost products and formulation disclosures.
3. Whether the claimed formulation produced unexpected clinical benefits sufficient to support nonobviousness.
4. Whether Allergan was entitled to an injunction delaying generic launch.

What was Watson’s Paragraph IV challenge?

Watson challenged the patent under Paragraph IV of the Hatch-Waxman Act. A Paragraph IV certification permits a generic applicant to assert that an Orange Book-listed patent is invalid or not infringed before the patent expires.

The certification created an artificial act of infringement under 35 U.S.C. § 271(e)(2), allowing Allergan to sue before Watson commercially marketed the product. The litigation therefore determined whether Watson could obtain FDA approval and launch before expiration of the asserted patent. [2]

How did the district court rule?

The district court ruled in Allergan’s favor. It found that Watson’s proposed generic product would infringe the asserted patent and rejected Watson’s obviousness challenge.

The district court accepted Allergan’s evidence that the 0.01% formulation produced a clinically meaningful reduction in hyperemia compared with the earlier 0.03% formulation. The court treated that evidence as an unexpected result supporting nonobviousness.

The ruling prevented Watson from launching its generic product during the relevant patent term. The district court’s judgment also established that an ANDA applicant could not avoid infringement merely by relying on the general disclosure of the active ingredient or by pointing to prior-art formulations that used a materially higher concentration.

What did the Federal Circuit decide in Allergan v. Watson?

The Federal Circuit affirmed the district court’s judgment for Allergan.

The appellate court’s analysis addressed the relationship between:

• The prior-art disclosure of bimatoprost ophthalmic formulations;
• The claimed 0.01% concentration;
• The objective evidence of reduced hyperemia; and
• The absence of a sufficient motivation to select the claimed concentration with a reasonable expectation of achieving the claimed clinical results.

The Federal Circuit agreed that the prior art did not establish that a skilled person would have selected the claimed 0.01% concentration for the purpose of reducing hyperemia while preserving therapeutic efficacy. The court also accepted the unexpected-results evidence as probative of nonobviousness. [1]

Why was the unexpected-results evidence important?

In pharmaceutical patent litigation, a claimed formulation can be vulnerable when the active ingredient, route of administration, and general dosage range were known. Allergan’s defense depended on showing that the specific formulation delivered an advantage that the prior art did not reasonably predict.

The relevant evidence included clinical data comparing Lumigan 0.01% with Lumigan 0.03%. Allergan argued that the lower concentration retained efficacy while reducing hyperemia. The Federal Circuit treated this comparative evidence as evidence that the claimed formulation was not an obvious optimization of a known product.

The decision illustrates that a lower dose or concentration is not automatically obvious. The patent owner must connect the claimed parameter to a demonstrated technical or clinical benefit and establish that the benefit was unexpected relative to the prior art.

What was the patent-strength assessment?

The litigation strengthened the commercial position of Allergan’s Lumigan 0.01% formulation patent.

Patent-strength factor	Assessment
Claim subject matter	Specific ophthalmic formulation
Infringement theory	ANDA product contained the claimed concentration
Prior-art risk	Significant because bimatoprost and ophthalmic formulations were known
Allergan’s principal defense	Unexpected reduction in hyperemia
Federal Circuit result	Judgment for Allergan affirmed
Generic-entry effect	Watson was blocked during the enforceable patent period
Commercial vulnerability	Concentration-specific claims remained stronger than broad active-ingredient claims

The strongest feature of Allergan’s estate was the connection between the 0.01% concentration and the clinical benefit. The principal vulnerability was that the claimed formulation represented a lower concentration of an already known ophthalmic drug. Without the clinical evidence, Watson’s obviousness argument would have been materially stronger.

When did Lumigan lose exclusivity?

FDA regulatory exclusivity and patent exclusivity were separate.

Lumigan’s original FDA exclusivity period expired before the Watson appeal. The remaining barrier was patent protection and any applicable pediatric-exclusivity or patent-term-adjustment period reflected in FDA records.

The asserted U.S. Patent No. 7,851,504 had a standard twenty-year term measured from its earliest effective nonprovisional filing date, subject to patent-term adjustment. The exact generic-launch date depended on the Orange Book listing, any applicable pediatric extension, the final judgment, and the terms of Watson’s ANDA approval.

The Federal Circuit decision did not create new FDA exclusivity. It upheld the patent-based barrier to approval and launch. [1][3]

What was the Orange Book status?

The Orange Book listed patent protection for Lumigan and related bimatoprost products. Orange Book listings identify patents that a generic applicant must address in an ANDA certification.

For commercial diligence, the relevant distinction is:

• FDA exclusivity controls when the agency may approve certain ANDAs.
• Orange Book-listed patents control the patent certifications required from an ANDA applicant.
• A Paragraph IV certification can trigger litigation and a potential 30-month stay of approval.
• The litigation judgment determines whether the generic can launch before patent expiration.

The Watson case addressed the patent dispute. It did not decide every patent or exclusivity issue affecting all bimatoprost products. [3]

What patent litigation affected generic Lumigan entry?

The Watson litigation was part of a broader patent challenge involving generic versions of Lumigan 0.01%. Other ANDA applicants, including Apotex and Sandoz, pursued related challenges to Allergan’s bimatoprost formulation patents.

The broader litigation landscape included:

• U.S. Patent No. 7,851,504, directed to the 0.01% bimatoprost formulation;
• Later continuation or related patents covering aspects of the same commercial product;
• Paragraph IV challenges by multiple generic manufacturers; and
• Separate Federal Circuit appeals addressing obviousness and claim scope.

The existence of multiple ANDA challengers increased the probability that a successful invalidity or noninfringement ruling by one applicant could affect the broader generic market. Conversely, affirmance in Allergan’s favor increased settlement leverage and delayed independent generic entry.

Did the case involve method-of-use patents?

The Watson appeal primarily concerned the formulation patent associated with Lumigan 0.01%, rather than a stand-alone method-of-use patent.

The product’s approved use was treatment of elevated intraocular pressure in glaucoma and ocular-hypertension patients. Method-of-use patents can create separate infringement questions when an ANDA label directs the patented use. In this litigation, however, the principal issue was whether the generic formulation itself fell within Allergan’s patented composition claims.

This distinction affected the strength of Allergan’s case. A formulation claim can be infringed based on the composition of the ANDA product, while a method-of-use claim may depend more heavily on the language of the proposed label and the applicant’s intended use.

What were the settlement and licensing implications?

The public appellate decision resolved the merits of the patent dispute but did not establish a commercial launch date or disclose a settlement agreement between Allergan and Watson.

In Hatch-Waxman matters, parties may resolve litigation through:

• A license permitting launch before patent expiration;
• A contingent license tied to another generic entrant;
• A supply or authorized-generic arrangement;
• A launch date after patent expiry; or
• Continued litigation through final judgment.

The appellate affirmance improved Allergan’s negotiating position because Watson did not obtain a ruling eliminating the asserted patent barrier. Any commercial agreement would need to be evaluated separately from the judicial holding.

What generic-entry risks remained after the decision?

The decision eliminated Watson’s immediate route to early entry based on invalidity or noninfringement. It did not remove all generic-entry risks for Allergan.

Remaining risks included:

1. A later successful challenge by another ANDA applicant.
2. Invalidation of a related continuation patent.
3. Noninfringement of claims not asserted against Watson.
4. Launch after patent expiration by one or more generic manufacturers.
5. FDA approval of products that avoided the specific patented concentration or formulation.
6. Commercial substitution pressure from authorized or licensed generics.

The practical value of the patent depended on claim breadth. Claims limited to a defined 0.01% concentration could block directly substitutable products but provide less protection against alternative concentrations, preservatives, excipients, or delivery systems.

How does Allergan’s Lumigan estate compare with competing ophthalmic products?

Lumigan competed in the prostaglandin analog market with latanoprost and travoprost products, including Xalatan and Travatan Z. The products shared the glaucoma treatment market but relied on different active ingredients and formulation technologies.

Product	Active ingredient	Primary patent-risk profile
Lumigan	Bimatoprost	Concentration-specific formulation and related product patents
Xalatan	Latanoprost	Compound, formulation, and method-of-use patents
Travatan Z	Travoprost	Formulation and preservative-system patents
Generic prostaglandin analogs	Various	Earlier compound and formulation patents generally expired or weakened

Lumigan’s differentiated commercial position depended partly on the 0.01% formulation’s tolerability profile. That made formulation patents commercially important even after broad market exclusivity for bimatoprost as an active ingredient had narrowed.

What were the commercial consequences for Allergan?

The judgment supported continued sales of Lumigan 0.01% without immediate Watson generic competition. The financial impact depended on Lumigan’s sales at risk, the number of additional ANDA filers, and the timing of generic approval after patent expiry.

The decision protected:

• Branded prescription revenue;
• Pricing before generic entry;
• Prescriber and formulary positioning;
• The value of Allergan’s ophthalmic formulation platform; and
• Negotiating leverage in future generic settlements.

It did not provide perpetual protection. Once the relevant patent barriers expired or were circumvented, generic bimatoprost products could erode price and volume rapidly.

What does Allergan v. Watson mean for pharmaceutical patent strategy?

The case supports several formulation-patent strategies:

• Claim a commercially important concentration rather than only the active ingredient.
• Generate comparative clinical evidence early.
• Link the formulation parameter to a measurable patient benefit.
• Preserve continuation applications covering alternative excipients, concentrations, and dosing regimens.
• Maintain Orange Book listing discipline.
• Prepare evidence showing why the claimed formulation was not a routine optimization.
• Anticipate Paragraph IV challenges from multiple generic applicants.

The case also shows that clinical tolerability data can determine the outcome of an obviousness dispute involving a known active pharmaceutical ingredient.

Key Takeaways

• Allergan v. Watson, No. 13-1249, concerned generic Lumigan 0.01% and bimatoprost formulation patent protection.
• The principal patent was U.S. Patent No. 7,851,504.
• Watson filed an ANDA with a Paragraph IV challenge.
• The district court found infringement and upheld the patent against obviousness challenges.
• The Federal Circuit affirmed the judgment for Allergan.
• Reduced hyperemia at the 0.01% concentration was central to Allergan’s unexpected-results evidence.
• The decision delayed Watson’s generic entry but did not eliminate later generic-entry risk.
• FDA exclusivity, Orange Book patent protection, and patent-term expiration remained separate legal issues.
• The case strengthened the value of concentration-specific formulation claims in ophthalmic drug litigation.

FAQs

What was the drug in Allergan v. Watson Pharmaceuticals?

The drug was Lumigan 0.01% ophthalmic solution, containing bimatoprost for glaucoma and ocular hypertension.

Which patent did Watson challenge?

Watson challenged Allergan’s U.S. Patent No. 7,851,504, covering an ophthalmic formulation containing 0.01% bimatoprost.

Did the Federal Circuit invalidate Allergan’s Lumigan patent?

No. The Federal Circuit affirmed the judgment for Allergan and upheld the district court’s treatment of the asserted patent.

Why did hyperemia matter in the litigation?

Hyperemia, or eye redness, was evidence of a clinical benefit associated with the lower-concentration 0.01% formulation. Allergan used that benefit to rebut Watson’s obviousness challenge.

Could another generic company still challenge Lumigan patents?

Yes. The decision resolved Watson’s appeal. Other ANDA applicants could pursue separate invalidity, noninfringement, settlement, or launch strategies involving the same or related patents.

References

1. Allergan, Inc. v. Watson Pharmaceuticals, Inc., No. 13-1249, United States Court of Appeals for the Federal Circuit.

2. Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355(j); 35 U.S.C. § 271(e)(2).

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.